Find clinical trials for Non-Hodgkin Lymphoma in Budapest, Budapest

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Lymphoma

B-Cell Lymphoma

Diffuse Large B-Cell Lymphoma

Leukemia

Lymphoid Leukemia

B-Cell Chronic Lymphocytic Leukemia

Cancer

Non-Hodgkin Lymphoma trials near Budapest, Budapest, HUN:

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)

The purpose of this study was to evaluate whether copanlisib in combination with rituximab is superior to placebo in combination with rituximab in pr...

Active, not recruiting

Lymphoma,Non-Hodgkin

Drug: Placebo

Drug: Copanlisib (Aliqopa, BAY80-6946)

Phase 3

Bayer

Budapest, Hungary and 186 other locations

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purp-...

Enrolling

Non-Hodgkin Lymphoma

Drug: Pirtobrutinib

Drug: Ibrutinib

Phase 2

Genmab

Budapest, Hungary and 74 other locations

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants with HGG and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

The primary purpose of the study is to evaluate whether biweekly administered XEMBIFY® plus Standard Medical Treatment (SMT) over a one-year period w...

Enrolling

Non-Hodgkin Lymphoma

Multiple Myleoma

Drug: Xembify

Drug: Placebo

Phase 3

Grifols

Budapest, Hungary and 38 other locations

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma....

Active, not recruiting

Lymphoma, Mantle Cell

Drug: Bendamustine

Drug: Acalabrutinib

Phase 3

Acerta Pharma

Budapest, Hungary and 227 other locations

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Multicenter, open-label, prospective treatment protocol that provides continued access to ibrutinib to subjects who have completed parent ibrutinib s...

Invitation-only

Lymphoma, B-Cell

Lymphoma, Non-Hodgkin

Drug: Ibrutinib

Phase 4

Pharmacyclics

Budapest, Hungary and 97 other locations

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)

in participants with relapsed/refractory diffuse large B-cell lymphoma, who are not eligible for high-dose chemotherapy and autologous stem ...

Active, not recruiting

Diffuse Large B-cell Lymphoma

Drug: R-GemOx or BR plus polatuzumab vedotin

Genetic: MB-CART2019.1

Phase 2

Miltenyi Biotec

Budapest, Hungary and 52 other locations

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), ma...

Enrolling

Non-Hodgkins Lymphoma

Waldenstroms Macroglobulinaemia

Drug: Nemtabrutinib

Phase 2

Merck Sharp & Dohme (MSD)

Budapest, Hungary and 120 other locations

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this dise...

Enrolling

Follicular Lymphoma (FL)

Drug: Lenalidomide

Drug: Epcoritamab

Phase 3

Genmab

Budapest, Hungary and 281 other locations

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this dise...

Enrolling

Follicular Lymphoma (FL)

Drug: Obinutuzumab

Drug: Rituximab

Phase 3

Genmab

Budapest, Hungary and 194 other locations

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The pur...

Enrolling

Diffuse Large B-Cell Lymphoma

Drug: Epcoritamab

Drug: Cyclophosphamide

Phase 3

Genmab

Budapest, Hungary and 338 other locations

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms

Find clinical trials for Non-Hodgkin Lymphoma in .css-epvm6{white-space:nowrap;}Budapest, Budapest

Related conditions:

Non-Hodgkin Lymphoma trials near Budapest, Budapest, HUN:

Copanlisib and Rituximab in Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (iNHL) (CHRONOS-3)

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants with HGG and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma (EPCORE FL-1)

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Find clinical trials for Non-Hodgkin Lymphoma in Budapest, Budapest